Reversal of Neuromuscular Blockade in Thoracic Surgical Patients
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The majority of patients undergoing surgery receive neuromuscular blocking agents (NMBAs) in
the operating room. Reversal of neuromuscular blockade at the conclusion of a general
anesthetic is accomplished with cholinesterase inhibitors (primarily neostigmine). Although
these drugs are often effective in enhancing recovery of muscle strength, the onset of effect
is often slow (usually 15-30 minutes). More effective neuromuscular reversal agents are
needed in clinical practice to enhance surgical and anesthetic management of perioperative
patients. A new reversal agent (sugammadex) will likely be approved for clinical use in the
United States next year. Unlike neostigmine, sugammadex is effective in providing rapid
antagonism of all levels of neuromuscular blockade (typically within 2-4 minutes). The aim of
this prospective observational study is to study neuromuscular and clinical recovery in 100
consecutive thoracic surgical patients receiving neostigmine, followed by a 100 consecutive
thoracic surgical patients administered sugammadex (after the drug is approved by the FDA).
In addition, after data on 100 patients reversed with neostigmine is collected, the data will
be analyzed to compare patients with residual block (train-of four < 0.9) and without
residual block (TOF
Details
Lead Sponsor:
NorthShore University HealthSystem NorthShore University HealthSystem Research Institute